Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Amgen logo
AmgenAMGN
$0
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$227K+1,035%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.61B+89.4%
Enterprise value$2.56B+99.4%
P/S36.7×-4,485×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
(in thousands) / June 30, 2026Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
U.S. treasury securities$322,051$(608)$321,443
Corporate paper and bonds495,6487(554)495,101
Total$817,699$7$(1,162)$816,544
December 31, 2025
U.S. treasury securities$223,526$254$(9)$223,771
Corporate paper and bonds438,297241(39)438,499
Total$661,823$495$(48)$662,270

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax)?
Viridian Therapeutics, Inc. (VRDN) reported unrealized losses on investments (before tax) of $1.16M in Q2 2026.
How has Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax) increased by 464.1% year-over-year, from $206K to $1.16M.
What is the long-term trend for Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax)?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax) has grown at a -26.3% compound annual growth rate (CAGR), from $163K to $48K.
What does unrealized losses on investments (before tax) mean?
The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.

Ask your AI about Viridian Therapeutics, Inc.'s unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude